Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y0GH
|
|||
| Former ID |
DAP000994
|
|||
| Drug Name |
Mitomycin
|
|||
| Synonyms |
Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Approved | [1], [2] | |
| Gastrointestinal cancer [ICD-11: 2C11] | Approved | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H18N4O5
|
|||
| Canonical SMILES |
CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N
|
|||
| InChI |
1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
|||
| InChIKey |
NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
|||
| CAS Number |
CAS 50-07-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8906, 87663, 613813, 7847275, 8144500, 8153525, 11120094, 11120582, 11121070, 11121809, 11122289, 11147177, 11363021, 11365583, 11368145, 11371173, 11371174, 11373746, 11376307, 14899962, 14924490, 15249200, 24896554, 24896555, 24896917, 26759169, 26759192, 29224783, 46508353, 47440503, 47440504, 47589205, 48414068, 48416286, 48423722, 49854359, 50064401, 50111457, 53787087, 56310827, 56311910, 56312869, 56312950, 56313687, 56313798, 56313799, 56314173, 56314310, 57260126, 57322926
|
|||
| ChEBI ID |
CHEBI:27504
|
|||
| ADReCS Drug ID | BADD_D01478 | |||
| SuperDrug ATC ID |
L01DC03
|
|||
| SuperDrug CAS ID |
cas=000050077
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Binder | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8. | |||
| REF 4 | Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.